Missionomics Back to app

Healthcare

Bristol Myers Squibb (BMY)

Healthcare $124.0B market cap

Data as of July 13, 2026

Environment
70.00
People
72.00
Leadership
75.00

Environment story

BMY demonstrates moderate environmental performance with ongoing investments in manufacturing efficiency and renewable energy integration. However, Scope 3 emissions disclosure remains insufficient, and the company has not articulated a credible net-zero target before 2050. Environmental remediation liabilities at 36 contaminated sites (15 current/former BMY facilities, 21 third-party PRP sites under CERCLA) represent material contingent costs. The company invests in facility improvements for energy and water efficiency but lacks transparency on absolute emissions reductions versus offset reliance. Greenwashing risk is elevated due to emphasis on aspirational ESG goals without disclosed operational decarbonization metrics.

Criticisms on file

  • Environmental Remediation Liabilities: 36 contaminated sites under investigation or remediation. BMY is PRP at 21 third-party waste disposal/reprocessing facilities. CERCLA liability exposure is unquantified.
    Source: BMY 10-K 2025, Item 1A Risk Factors—Manufacturing and Quality Assurance; Item 8 Note 20 Legal Proceedings and Contingencies
  • Scope 1, 2, 3 Emissions Undisclosed: Company provides no quantitative greenhouse gas emissions data in 10-K, no renewable energy percentage, no net-zero target year. ESG commitments are aspirational without verifiable baselines.
    Source: BMY 10-K 2025, Item 1A Risk Factors—Expectations relating to environmental, social and governance considerations
  • Greenwashing Risk: Company publicly announces ESG goals and commitments but implementation depends on third-party performance outside BMY's direct control. Failure to meet goals could result in shareholder litigation and reputational damage.
    Source: BMY 10-K 2025, Item 1A Risk Factors—Expectations relating to environmental, social and governance considerations and related reporting obligations

Disclosed initiatives

  • Manufacturing Facility Capital Investment
    Ongoing investment in Devens (MA), Leiden (Netherlands), Indianapolis (IN) facilities; completed new cell-therapy manufacturing facility in Leiden (2025) and radiopharmaceutical facility in Indianapolis (2025). R&D facilities opened in Cambridge, MA (2023) and Hyderabad, India (2024); planned San Diego facility (2026).
    Supports future supply continuity and manufacturing standardization; unclear whether these investments include decarbonization infrastructure vs. standard compliance upgrades.
  • Energy and Water Efficiency Projects
    Company states investment in projects reducing resource use of energy and water. Operating and capital costs for environmental compliance stated as not material in 2025, 2024, 2023.
    Minimal documented impact; lack of quantified baseline and target reduction metrics weakens credibility.
  • Environmental Compliance Program
    Environment, occupational health, safety and sustainability group monitors global operations and implements compliance standards. Substantial compliance with environmental, health and safety requirements stated.
    Reactive compliance posture; no evidence of proactive decarbonization or emissions reduction targets.

Social story

BMY's social performance is mixed. The company maintains a global workforce of ~32,500 across 43 countries (54% US, 46% international) with stated commitment to inclusive culture, employee development, and competitive compensation. However, CEO-to-worker pay ratio is not disclosed, limiting verification of pay equity claims. Turnover rates are undisclosed. Union standing is neutral (no documented NLRB complaints, strikes, or suppression activities in recent filings, but no evidence of proactive labor cooperation). Diversity metrics in leadership are mentioned but specific percentages for women and underrepresented groups in executive/board roles are not provided in 10-K. Supply-chain human-rights risks exist in manufacturing and raw-materials sourcing (e.g., reliance on third-party suppliers for active pharmaceutical ingredients) but no formal audit or conflict-minerals policy is disclosed in 10-K.

Criticisms on file

  • CEO-to-Worker Pay Ratio Undisclosed: Company does not provide CEO-to-median-worker pay ratio in 10-K or proxy, preventing assessment of pay equity and alignment with social standards.
    Source: BMY 10-K 2025 and 2026 Proxy Statement—CEO compensation disclosed but worker median wage/pay ratio not provided
  • Diversity Metrics Incomplete: Proxy and 10-K reference commitment to inclusive workplace and diversity but do not disclose percentages of women and underrepresented groups in executive leadership or board. Board composition shown but workforce demographics undisclosed.
    Source: BMY 10-K 2025 Item 1 Human Capital Management and Resources; 2026 Proxy Statement—board diversity stated but quantified metrics absent
  • Supply-Chain Human-Rights Oversight: Company relies on third-party manufacturers for active pharmaceutical ingredients (Eliquis, Opdivo, Pomalyst, Yervoy, Zeposia, Sotyktu, Cobenfy, etc.). No formal conflict-minerals audit, forced-labor policy, or supply-chain ethics certification disclosed.
    Source: BMY 10-K 2025 Item 1A Risk Factors—Sources and Availability of Raw Materials; Manufacturing and Quality Assurance

Disclosed initiatives

  • People Strategy and Culture
    Designed to empower employees, foster inclusive workplace, accelerate personal and business growth. Core values stated as Integrity, Passion, Inclusion, Innovation, Accountability, Urgency. Annual employee sentiment surveys on culture, values, execution, engagement.
    Stated commitment to inclusion but no quantified diversity targets or third-party verification disclosed.
  • Career Growth and Development
    Investment in next-generation platforms for internal mobility, democratization of learning resources, AI upskilling. Full suite of leadership development resources emphasizing 'everyone as a leader.'
    Supports talent retention but effectiveness metrics are undisclosed.
  • Compensation and Well-being Programs
    Market-competitive base salaries, annual incentives tied to company and individual performance, long-term equity incentives, holistic well-being benefits, peer recognition.
    Stated competitive positioning; CEO-to-worker ratio and pay equity audits not disclosed, limiting verification.
  • Occupational Health & Safety
    Comprehensive in-house occupational health service, early identification of work-related illness, protection protocols for employees, contractors, visitors.
    Preventive approach to occupational health; specific incident rates or injury statistics not disclosed in 10-K.

Governance story

BMY exhibits solid governance with 10 of 11 board members independent (91%), robust committee structure (Audit, Compensation, Directors & Corporate Governance, Science & Technology), and annual board refreshment (4 new directors in past 5 years). However, combined CEO-Chair structure (Christopher Boerner holds both) creates concentrated power despite presence of strong Lead Independent Director (Theodore Samuels). Single-class share structure with majority voting. Board actively oversees risk, strategy, and compliance. Shareholder engagement is transparent with proxy annual advisory votes on compensation and ratification of auditors. No disclosed antitrust proceedings, SEC consent decrees, or major fines in recent 10-K filings. Lobbying expenditure is not itemized in 10-K but company acknowledges pharmaceutical industry regulatory pressures and political dynamics. Governance risk is moderate; the combined CEO-Chair role, while justified by board as operationally efficient, lacks independent safeguards typical of best-practice governance.

Criticisms on file

  • Combined CEO-Chair Structure: Christopher Boerner serves as both CEO and Board Chair. While board justifies this as operationally efficient given his institutional knowledge, it concentrates power and limits independent oversight compared to best-practice governance. Shareholder John Chevedden proposed (Item 5, 2026 proxy) that board adopt policy requiring independent chairman; board recommended vote against.
    Source: BMY 2026 Proxy Statement—Board Leadership Structure discussion (page 31-32); Item 5 Shareholder Proposal on Independent Board Chairman
  • Shareholder Governance Proposal Rejected: Proposal requesting independent board chairman received board recommendation against adoption, despite governance best-practice trend toward separation of CEO and Chair roles in Fortune 500 companies.
    Source: BMY 2026 Proxy Statement Item 5—Shareholder Proposal on Adoption of Board Policy that Chairperson of Board be an Independent Director
  • Lobbying and Political Engagement Undisclosed: Company does not itemize annual lobbying expenditures or disclose specific legislative positions advocated in 10-K. Given pharmaceutical industry's focus on pricing regulation, tax policy, and healthcare reform, lack of transparency on lobbying spend and positions is governance risk.
    Source: BMY 10-K 2025 Item 1A Risk Factors—references extensive regulatory and legislative pressures but does not disclose lobbying spend or specific advocacy positions
  • Pricing Pressures and Government Negotiations: In December 2025, BMY announced U.S. Government Agreement providing Eliquis free to Medicaid, donating API to Strategic Reserve, offering 80% discounts on other drugs, and adopting 'balanced pricing' for new launches. This agreement, negotiated under Trump administration pressure, suggests potential governance vulnerability to executive branch negotiating power and lack of transparent policy advocacy.
    Source: BMY 10-K 2025 Item 1A Risk Factors—Increased pricing pressure; U.S. Government Agreement details in Risk Factors section
  • Stock Price Decline and Clinical Trial Failures: Shareholder proposal (Item 5, 2026 proxy) notes BMY stock fell from $77 (2016) to $43 (late 2025). Multiple failed Phase 3 trials in 2025 (Cobenfy schizophrenia add-on, Mavacamten heart disease, Reblozyl myelofibrosis anemia) and 38% Revlimid sales decline due to generics raise questions about strategic execution and pipeline management oversight by board.
    Source: BMY 2026 Proxy Statement Item 5—Shareholder Proposal statement citing failed trials and stock performance

Disclosed initiatives

  • Independent Board Leadership with Lead Director
    Theodore Samuels serves as Lead Independent Director with defined responsibilities: liaison between independent directors and CEO, approval of board information and agendas, presiding at executive sessions, engaging with shareholders. Board evaluates leadership structure annually.
    Provides structured independent oversight counterbalance to combined CEO-Chair role. Lead Director responsibilities are well-defined and transparent.
  • Board Committees with Independent Composition
    All standing committees (Audit, Compensation & Management Development, Directors & Corporate Governance, Science & Technology) composed entirely of independent directors. Each has written charter, defined oversight scope, and regular meeting cadence (Audit: 8 meetings; Compensation: 6 meetings; Directors: 3 meetings; Science & Technology: 4 meetings in 2025).
    Ensures independent oversight of financial reporting, executive compensation, board composition, R&D strategy, and risk management.
  • Annual Board and CEO Evaluation
    Board conducts annual evaluation of Board performance and CEO effectiveness. Results inform board composition and leadership structure decisions.
    Provides mechanism for continuous governance improvement and director accountability.
  • Majority Voting Standard for Directors
    Directors must receive majority of votes cast in non-contested elections. Incumbent directors who fail to receive majority vote must tender irrevocable resignations contingent on board acceptance.
    Ensures director accountability to shareholders; all current director nominees have submitted required resignations.
  • Risk Oversight and Strategic Planning
    Board holds annual strategy deep-dives (typically Q2 and Q4) reviewing long-term operating plans, corporate strategy, and key risks. CEO leads discussion of risk mitigation. Board met 18 times in 2025 (7 regular, 11 special).
    Demonstrates active board engagement on strategy, risk, and execution; high meeting frequency shows substantive oversight.
  • Codes of Conduct and Compliance
    Company maintains Code of Business Conduct and Ethics for Directors, Code of Ethics for Senior Financial Officers, and Principles of Integrity. Codes available on website; waivers and material amendments posted promptly.
    Establishes ethical baseline and transparency for director conduct.
  • Compensation Risk Assessment
    Compensation and Management Development Committee annually reviews compensation policies for risk-taking incentives. Concluded that policies are balanced and do not incentivize imprudent risk. Design features include balance of fixed/variable compensation, clawback provisions, multiple performance metrics, share ownership guidelines, and caps on payouts.
    Mitigates risk of excessive executive risk-taking or misalignment with shareholder interests.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Bristol Myers Squibb. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Bristol Myers Squibb in the app for interactive charts and portfolio building.

Open Bristol Myers Squibb in Missionomics

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)

Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics